OMecaMtiv Mecarbil

Description

Omecamtiv mecarbil, a cardiac-specific myosin activator, is being tested for?treating left ventricle systolic heart failure. Myosin is present in “fast” and “slow” ATP-hydrolyzing forms; heart disease patients are often deficient in the fast form. Omecamtiv mecarbil binds to both forms to boost ATP hydrolysis and therefore heart function.

The Uses of OMecaMtiv Mecarbil

CK 1827452 is a promising new drug in systolic heart failure. It accelerates the transition of myosin into the force-generating state without affecting cardiac myocyte calcium homeostasis. CK 1827452 increases cardiac function by increasing the duration of ejection without changing the rates of contraction.

The Uses of OMecaMtiv Mecarbil

CK 1827452 is a promising new drug in systolic heart failure. It accelerates the transition of myosin into the force-generating state without affecting cardiac myocyte calcium homeostasis. CK 1827452 increases cardiac function by increasing the duration of ejection without changing the rates of contraction.

Definition

ChEBI: Omecamtiv mecarbil is a member of ureas.

Biological Activity

omecamtiv mecarbil (ck-1827452) is the first potent cardiac myosin activator that can specifically activate the cardiac myosin s1 domain but not other muscle myosins. in

References

1. malik fi1, hartman jj, elias ka, morgan bp, rodriguez h, brejc k, anderson rl, sueoka sh, lee kh, finer jt, sakowicz r, baliga r, cox dr, garard m,godinez g, kawas r, kraynack e, lenzi d, lu pp, muci a, niu c, qian x, pierce dw, pokrovskii m, suehiro i, sylvester s, tochimoto t, valdez c, wang w,katori t, kass da, shen yt, vatner sf, morgans dj. cardiac myosin activation: a potential therapeutic approach for systolic heart failure. science. 2011 mar 18;331(6023):1439-43.